Detalhe da pesquisa
1.
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Cell
; 161(2): 319-32, 2015 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-25843629
2.
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
Cell
; 156(4): 744-58, 2014 Feb 13.
Artigo
Inglês
| MEDLINE | ID: mdl-24529377
3.
MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
Blood
; 142(14): 1219-1232, 2023 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37467575
4.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Blood
; 142(10): 878-886, 2023 09 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37319435
5.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Blood
; 142(2): 141-145, 2023 07 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37130017
6.
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Blood
; 137(10): 1353-1364, 2021 03 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32871584
7.
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Blood
; 134(23): 2059-2069, 2019 12 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31697809
8.
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Blood
; 133(1): 70-80, 2019 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30322870
9.
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.
Blood
; 134(26): 2369-2382, 2019 12 26.
Artigo
Inglês
| MEDLINE | ID: mdl-31697821
10.
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Blood
; 134(14): 1144-1153, 2019 10 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31409671
11.
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Blood
; 134(1): 22-29, 2019 07 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30952672
12.
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.
Blood
; 132(8): 825-836, 2018 08 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29880615
13.
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Haematologica
; 105(5): 1361-1368, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31471373
14.
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Blood
; 130(21): 2265-2270, 2017 11 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29167175
15.
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Blood
; 130(3): 267-270, 2017 07 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28490569
16.
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Blood
; 129(23): 3071-3073, 2017 06 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28356247
17.
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Blood
; 130(22): 2420-2430, 2017 11 30.
Artigo
Inglês
| MEDLINE | ID: mdl-28893733
18.
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Proc Natl Acad Sci U S A
; 113(21): 5999-6004, 2016 May 24.
Artigo
Inglês
| MEDLINE | ID: mdl-27162338
19.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
N Engl J Med
; 372(4): 311-9, 2015 Jan 22.
Artigo
Inglês
| MEDLINE | ID: mdl-25482239
20.
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Blood
; 127(18): 2203-13, 2016 05 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26773040